StoneX Group’s Emergent Biosolutions EBS Stock Holding History

StoneX Group’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,367	Closed	-$26.2K	–	393
2024 Q1	$26.2K	Buy	+10,367	New	+$23.4K	0.01%	307

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

StoneX Group's EBS Position: Q2 2024 in Review

StoneX Group sold out of Emergent Biosolutions (EBS) in Q2 2024, closing a stake of 10,367 shares — an estimated $26.2K sold.

StoneX Group first reported a position in EBS in Q1 2024 and held it in 1 quarter. The position peaked at $26.2K in Q1 2024. 141 funds tracked by Wall St. Rank hold EBS as of Q2 2024.

StoneX Group reported no remaining Emergent Biosolutions position as of Q2 2024 after selling out during the quarter.
StoneX Group sold 10,367 Emergent Biosolutions shares in Q2 2024, an estimated $26.2K.
StoneX Group first reported a position in Emergent Biosolutions in Q1 2024 and held it in 1 quarter.
StoneX Group's Emergent Biosolutions position peaked at $26.2K in Q1 2024.
141 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2024.

Based on StoneX Group's 13F filing for Q2 2024, filed 7 Aug 2024.